SRR1349056
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1354446 | GTEX | — | 0.989 |
| 2 | SRR1360563 | GTEX | — | 0.979 |
| 3 | SRR1474553 | GTEX | — | 0.978 |
| 4 | SRR1367943 | GTEX | — | 0.976 |
| 5 | SRR1500753 | GTEX | — | 0.976 |
| 6 | SRR814989 | GTEX | — | 0.975 |
| 7 | SRR1084842 | GTEX | — | 0.974 |
| 8 | SRR1471943 | GTEX | — | 0.970 |
| 9 | SRR1408208 | GTEX | — | 0.969 |
| 10 | SRR660626 | GTEX | — | 0.968 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 6 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.365 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.321 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.276 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.202 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.120 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.054 | Inavolisib | — uncovered |